Non Invasive Diagnostic of Endometrial Receptivity NCT01588223

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

The purpose of this study is to determine a lipidomic profile on the endometrial fluid, that can predict endometrial receptivity.

Recruitment information / eligibility
Status	Completed
Enrollment	40
Est. completion date	May 2012
Est. primary completion date	May 2012
Accepts healthy volunteers	Accepts Healthy Volunteers
Gender	Female
Age group	18 Years to 35 Years
Eligibility	Inclusion Criteria: - Oocyte donors undergoing controlled ovarian stimulation - Regular menstrual cycles - no abnormal karyotype - generally healthy - BMI 19-29 Kg/m2 (both inclusive) - 18 to 35 years old. Exclusion criteria: -patients diagnosed with endometriosis and/or endometritis.

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Other:
• Lipid identification
The lipids are identified using Mass Spectrometry

Locations
Country	Name	City	State
Spain	IVI Valencia	Valencia

Sponsors *(1)*
Lead Sponsor	Collaborator
Igenomix

Spain,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Levels of lipids in the endometrial fluid as a diagnostic factor.		1 year	No